Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARMANI-2/ENGIC08 switch maintenance trial in advanced HER2-negative PD-L1-positive gastroesophageal adenocarcinoma
2025-524048-36-00Phase 3Authorised
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Aug 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of paclitaxel, ramucirumab and tislelizumab in gastroesophageal junction adenocarcinoma (2 arms), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Progression-free survival. Planned start Aug 2026; status: authorised.
02
Drugs
paclitaxelramucirumabtislelizumab
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2025-524048-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524048-36-00.